To this aim, we treated the three cell lines (ALL-SIL, MOLT-4 and RPMI-8402) with a JAK1/2-STAT6 activation profile comparable to T-LBL pediatric patients with worse prognosis, with ruxolitinib alone or in combination with dexamethasone. The gene discussed is STAT6; the disease is acute lymphoblastic leukemia.